Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) Drops by -8.7% - Insider Trading Report Print

Rockwell Medical, Inc. (NASDAQ:RMTI) has lost 8.7% during the past week and dropped 23.86% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 3.11%. Rockwell Medical, Inc. (NASDAQ:RMTI) has underperformed the index by 19.66% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

For the current week, the company shares have a recommendation consensus of Buy. Rockwell Medical, Inc. (NASDAQ:RMTI) rose 4.52% or 0.5 points on Friday and made its way into the gainers of the day. After trading began at $10.66 the stock was seen hitting $11.88 as a peak level and $10.66 as the lowest level. The stock ended up at $11.55. The daily volume was measured at 1,072,987 shares. The 52-week high of the share price is $18.8999 and the 52-week low is $8.095. The company has a market cap of $580 million. Rockwell Medical, Inc. is up 9.9% in the last 3-month period. Year-to-Date the stock performance stands at 12.35%. The company shares have rallied 24.06% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $18.9 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $14.9 and the 200 day moving average is recorded at $12.18. S&P 500 has rallied 1.35% during the last 52-weeks. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at $11.96 per share with total amount equaling $58,724. Rockwell Medical, Inc. (NASDAQ:RMTI) stock has received a short term price target of $ 15 from 6 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $8.15. The higher estimate of target price is $26 , while the lower price target estimate is $4 Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.